Document:

RESEARCH
      AND LICENSE AGREEMENT

    (HVC)

    

    

    This
      agreement (the "Agreement")
      is
      made and entered into as of the 30 day of May, 2005 (the "Effective
      Date")
      by and
      between Rosetta
      Genomics Ltd.,
      a
      private company registered under the laws of the State of Israel, of 10 Plaut
      Street, Science Park, Rehovot, Israel ("Rosetta")
      and
Hadasit
      Medical Research Services and Development Ltd.,
      a
      private company registered under the laws of the state of Israel, of Hadassah
      Medical Hospital, POB 12000, Jerusalem, Israel ("Hadasit").

    

    WHEREAS,
      Rosetta is engaged in research and development in the field of bioinformatics
      and molecular biology detection, prediction and discovery of MicroRNA sequences
      and their respective functions and utilities, and therapeutic and diagnostic
      uses based thereon, in the course of which Rosetta has discovered and filed
      patents for a large number of MircoRNAs and their respective functions and
      utilities; and

    

    WHEREAS,
      Hadasit is a subsidiary of Hadassah Medical Organization ("HMO")
      and is
      charged with the commercial exploitation of the intellectual property and other
      potentially valuable assets of HMO; and

    

    WHEREAS,
      Prof. Eithan Galum (the "Principal
      Investigator")
      from
      the Goldyne Savad Institute of Gene Therapy at the Hadassah Hebrew University
      Hospital ("HUH")
      has
      expertise in the field of viral infection of HVC research; and

    

    WHEREAS,
      Rosetta and Hadasit have previously negotiated a Principles of a Joint Research
      Agreement (the "Joint
      Research Memorandum"),
      which
      defines the main principles pursuant to which Rosetta and the Principal
      Investigator will collaborate in the performance of certain Research (as defined
      below) relating to the suppression of viral activity of HCV by using MicroRNAs;
      and

    

    Suppress
      viral infection of HCV by using HCV and human MicroRNAs over expression or
      silencing. Show results on animal model.

    

    WHEREAS,
      the parties wish to set forth herein the definitive terms of the collaboration
      of the parties with respect to the performance of the Research and the future
      utilization of its results, which terms will supersede and replace the Joint
      Research Memorandum;

    

    NOW
      THEREFORE, the parties, intending to be legally bound, hereby agree as
      follows:

    

    1. 
Interpretation

    

    1.1 In
      this
      Agreement, each of the following terms shall have the meaning set forth opposite
      it, unless the context otherwise requires:

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    1.1.1 "Affiliate"
      shall
      mean, with respect to a party, any person, organization or entity controlling,
      controlled by or under common control with, such party. For purposes of this
      definition only, "control" of another person, organization or entity shall
      mean
      the possession, directly or indirectly, of the power to direct or cause the
      direction of the activities, management or policies of such person, organization
      or entity, whether through the ownership of voting securities, by contract
      or
      otherwise.

    

    1.1.2 "Combination
      Product"
      shall
      mean a product, substance or device which is not an internal development of
      Rosetta derived from the Results under this Agreement, and which incorporates
      a
      product based on the Results or Joint Patents and at least one other essential
      additional ingredient, substance, compound or element which either (i) when
      administered to a patient, has a therapeutic or prophylactic clinical effect,
      either directly or by acting synergistically with other compounds or substances
      contained in such product, (ii) is required for delivery of another compound
      or
      substance contained in such product or (iii) otherwise enhances the effect
      another compound or substance contained in such product.

    

    1.1.3 "Field"
      shall
      mean the field of MicroRNA based therapeutic related to HCV.

    

    1.1.4 "Hadasit
      IP"
      shall
      mean any and all Intellectual Property that Hadasit has developed or will
      develop, or which Hadasit owns or will otherwise own, excluding the
      Results.

    

    1.1.5 "Intellectual
      Property"
      shall
      mean all intellectual property, whether or not protected by patents or patent
      applications, including, but not limited to, trade secrets, procedures,
      protocols, inventions, moral rights, drawings, trade marks, databases, know
      how,
      inventions, improvements, discoveries, conceptions, ideas, techniques, designs,
      products, developments, specifications, methods, drawings, diagrams, models,
      software programs, data, data analysis, data interpretation, written reports,
      and all rights therein including copyright, patent rights, database rights,
      rights in designs and all registrations and applications therefore, and all
      continuations, continuations in part, divisional applications, and renewals
      of
      any of the foregoing, in any part of the world.

    

    1.1.6 "Joint
      Patents"
      shall
      mean any joint patent or patent application relating to the
      Results.

    

    1.1.7 "License"
      shall
      mean the license granted under Section 7 below.

    

    1.1.8 "Licensed
      IP"
      shall
      mean the Results, the Joint Patents and any other Intellectual Property
      underlying the results.

    

    1.1.9 "Net
      Revenues"
      shall
      mean the gross amount received by or on behalf of Rosetta or its Affiliates
      in
      connection with the commercialization of the Results or Joint Patents, less
      the
      following: (a) credits, refunds, rebates or trade, quantity, or cash discounts
      to the extent actually allowed and taken; (b) amounts repaid or credited by
      reason or rejection or return; (c) any taxes or other governmental charges
      levied on the production, sale, transportation, import, export, delivery or
      use
      of the product; and (d) outbound transportation, packing and delivery charges,
      as well as prepaid freight (including shipping insurance) actually incurred;
      provided however, that:

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    (i) In
      any
      transactions between Rosetta and an Affiliate, Net Revenues shall be only the
      total amount invoiced by such Affiliate on resale to an independent third party
      purchaser, in each case, after appropriate deductions as set forth
      above;

    

    (ii) In
      the
      event that Rosetta or its Affiliate receives non-monetary consideration for
      any
      transaction, Net Revenues shall be calculated based on the fair market value
      of
      such consideration, except that with respect to Net Revenues received in the
      form of equity, Rosetta shall have the right in its sole discretion or either
      pay Royalties in kind or based on the fair market value of such equity;
      and

    

    (iii) In
      the
      event a product is sold by Rosetta, an Affiliate of Rosetta or a sublicense
      of
      Rosetta in the form of a Combination Product, Net Revenues from such Combination
      Product, for purposes of determining Royalties, shall be determined by
      multiplying the actual Net Revenues of such Combination Product during the
      applicable royalty reporting period, by the fraction A/(A+B) where: A is the
      average sale price of the product based on the Results or Joint Patents that
      is
      contained in the Combination Product when sold separately; and B is the average
      price of the other ingredient, substance, compound or element included in the
      Combination Product when sold separately, in each case during the applicable
      royalty reporting period or if sales of both the products based on the Results
      or Joint Patents and/or other ingredient, substance, compound or elements did
      not occur in such period, then in the most recent royalty reporting period
      in
      which sales of both occurred. In the even that such average sale price cannot
      be
      determined for both the product based on the Results or Joint Patents and all
      other ingredients, substances, compounds or elements included in the Combination
      Product, Net Revenues for the purpose of determining Royalties shall be
      calculated by multiplying the Net Revenues of the Combination Products by the
      fraction of C/C+D where C is the fair market value of all other ingredients,
      substances, compounds or elements included in the Combination Product. In such
      event, the parties shall negotiate in good faith to arrive at a determination
      of
      the respective fair market values of the product based on the Results or Joint
      Patent and all other additional ingredients included in the Combination
      Product.

    

    For
      the
      sake of clarity, Net Revenues shall not include amounts received by Rosetta
      as
      grants or other funding.

    

    1.1.10 "Research"
      shall
      mean the joint research project of Rosetta and the Principal Investigator
      intended to suppress viral activity of HCV by using HCV and human MircoRNAs
      over
      expression or silencing, all as specified in the Research Program.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    1.1.11 "Research
      Program"
      shall
      mean the detailed program for the performance of the Research attached as
Annex
      A
      hereto.

    

    1.1.12 "Researched
      MircoRNAs"
      shall
      mean a defined subset of MicroRNAs identified by Rosetta.

    

    1.1.13 "Research
      Period"
      shall
      mean a period of 12 months commencing on the Effective Date.

    

    1.1.14 "Results"
      shall
      mean MicroRNAs identified by the parties within the framework and as a result
      of
      the Research, together with any other results of the Research in the
      Field.

    

    1.1.15
      "Rosetta
      MicroRNAs"
      shall
      mean any novel human and non-human (including virus and bacteria) MicroRNAs
      and
      tiny RNAs predicted or which may be predicted by Rosetta.

    

    1.1.16 "Rosetta
      IP"
      shall
      mean any and all Intellectual Property that Rosetta has developed or will
      develop, or which Rosetta owns or will own, including but not limited to the
      Rosetta MicroRNAs, but excluding the Results.

    

    1.2 The
      headings in this Agreement are inserted for convenience of reference only and
      shall not affect its interpretation.

    

    1.3 The
      preamble and annexes to this Agreement form an integral part of this
      Agreement.

    

    2. Joint
      Research

    

    The
      parties will cooperate in performance of the Research pursuant to the following
      terms and conditions:

    

    2.1 Hadasit
      shall be responsible to procure the performance of the Research in accordance
      with the Research Program, insofar as it relates to tasks listed in the Research
      Program under the responsibility of the Principal Investigator (the
      "PI
      Tasks"),
      as
      follows:

    

    2.1.1 The
      PI
      Tasks will be performed in accordance with the Research Program at and with
      the
      facilities and materials of HUH.

    

    2.1.1 The
      PI
      Tasks will be performed by the Principal Investigator, who may be assisted
      by
      skilled staff of HUH under the direct supervision of the Principal
      Investigator.

    

    2.1.3 The
      PI
      Tasks will be performed during the Research Period.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    2.1.4 Subject
      to Section 8.7 below, Hadasit will bear the expenses incurred by it, HUH and
      the
      Principal Investigator in the performance of the PI Tasks and any other
      obligations of Hadasit related to the Research or set forth herein.

    

    2.2 Rosetta
      shall be responsible to procure the performance of the Research in accordance
      with the Research Program, insofar as it relates to tasks listed in the Research
      Program under the responsibility of Rosetta (the "Rosetta
      Tasks"),
      as
      follows:

    

    2.2.1 The
      Rosetta Tasks will be performed by Rosetta in accordance with the Research
      Program at and with the facilities and materials of Rosetta.

    

    2.2.2 The
      Rosetta Tasks will be performed by skilled personal of Rosetta.

    

    2.2.3 The
      Rosetta Tasks will be performed during the Research Period.

    

    2.2.4 Rosetta
      will bear the expenses incurred by it in the performance of the Rosetta Tasks
      and any other obligations of Rosetta related to the Research or set forth
      herein.

    

    2.3 Each
      of
      the parties hereby undertakes to take all reasonable measures in order to ensure
      that it shall not utilize, in the course of performing its respective tasks
      under the Research Program, any intellectual property, technology or know-how
      infringing any third party intellectual property rights.

    

    2.4 During
      the performance of the Research, the research teams of Rosetta and the Principal
      Investigator will periodically meet or otherwise be in contact in order to
      update each other on the progress of the Research, provide information and
      material regarding interim Results, and in order to coordinate further Research
      activities. Each party shall prepare and maintain detailed records of , and
      regularly and reasonably promptly disclose in writing to the other Parties
      in
      reasonable detail, any and all inventions created, invented, developed,
      conceived or reduced to practice by or for such Party (including by its
      employees, affiliates, agents and consultants) in connection with the Research
      Program.

    

    2.5 The
      parties shall exchange final written reports regarding the Results they
      respectively achieved in the course of performance of the Research, by not
      later
      than thirty (30) days following the end of the Research Period. Hadasit will
      further provide Rosetta with any and all required documentation, information
      and
      material related to the Results achieved by the Principal Investigator, in
      such
      manner as will enable Rosetta to utilize an commercialize the Results pursuant
      to the terms of the License set forth herein.

    

    2.6 The
      parties, including the Principal Investigator and his research team, will
      further cooperate, to the extent requested by Rosetta, in order formalize joint
      documentation describing the Results, and in order to provide any other document
      or information which may be required in order to file Joint
      Patents.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    2.7 Either
      party may conduct additional research projects, independently or with other
      third parties in parallel to or following the Research and nothing in this
      Agreement shall prevent the parties from engaging in any additional research,
      provided that it fulfills its obligations hereunder.

    

    2.8 Hadasit
      represents and warrants that it is legally authorized and entitled to assume
      all
      responsibilities under this Agreement, including pertaining to any undertaking
      related to or obligating the Principal Investigator, the HUH and the HMO, as
      the
      case may be.

    

    2.9 If
      Dr.
      Eithan Galum ceases to serve as a Principal Investigator for any reason, Hadasit
      shall promptly notify Rosetta and use its best efforts to replace him by a
      substitute of similar experience and expertise within 30 days of such notice,
      and Rosetta may terminate this Agreement if it does not approve such substitute
      within 60 days from the date of such notice or I no such substitute is not
      fund
      within such time.

    

    3. 
Intellectual
      Property

    

    3.1 The
      Rosetta IP belongs solely to Rosetta which is and shall remain its sole owner.
      Nothing in this Agreement shall constitute or be considered as constituting
      a
      transfer or license of the Rosetta IP or any part thereof (including but not
      limited to the Rosetta MicroRNAs) by Rosetta to Hadasit, except to the limited
      extent necessary to allow Hadasit to perform its obligations under this
      Agreement.

    

    3.2 The
      Hadasit IP belongs solely to Hadasit which is and shall remain its sole owner.
      Nothing in this Agreement shall constitute or be considered as constituting
      a
      transfer or license of the Hadasit IP or any part thereof by Hadasit to
      Rosetta.

    

    3.3 All
      right, title and interest in and to the Results, whether or not they shall
      be
      protected by Joint Patents or other intellectual property rights, vest and
      shall
      vest in equal undivided shares with Hadasit and Rosetta.

    

    4. 
Joint
      Patents

    

    At
      the
      initiative of either Party the Parties will consult with each other whether
      to
      file any patent applications for Joint Patents relating to the Results or any
      part thereof. The following provisions will apply to any such patent
      applications for Joint Patents:

    

    4.1 Any
      Joint
      Patent will be listed in Annex
      B
      to this
      Agreement, which will be amended from time to time by written consent of Rosetta
      and Hadasit.

    

    4.2 The
      Joint
      Patents will be registered as jointly owned by Hadasit and Rosetta, in equal
      undivided shares. The Principal Investigator and inventor(s) designated by
      Rosetta will be registered as the investors of each Joint Patent. If the law
      of
      any jurisdiction in which an application for a Joint Patent is filed requires
      the application to be filed in the name of the inventors, the Parties will
      use
      their best efforts to procure that the Principal Investigator and any other
      inventors of the patent will cooperate in so filing the application for the
      patent and will thereafter assign the application to the Parties.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    4.3 Rosetta
      shall bear and pay all expenses relating to the prosecution and maintenance
      of
      the Joint Patents and shall control the prosecution, maintenance and litigation
      of the Joint Patents.

    

    4.4 The
      prosecution and maintenance actions include but are not limited to preparing,
      filing, prosecuting and maintaining patent and patent applications for the
      Joint
      Patent, managing any proceedings relating to any interferences or
      reexaminations, or requesting reissues or patent term extensions with respect
      to
      the Joint patent and resolving to file the Joint Patent in additional
      jurisdictions other than the initial jurisdiction in which it shall be filed,
      for the purpose of obtaining wider protection for the Joint Patent.

    

    4.5 In
      the
      event that Rosetta elects not to bear the expenses relating to the filing of
      a
      Joint Patent in a specific file or jurisdiction in which it has been already
      filed as a patent application, the following terms will apply:

    

    4.5.1 Rosetta
      shall give Hadasit prior written notice within a reasonable time prior to the
      date in which such expense is due, including all relevant details regarding
      the
      expense, and specifically indicate its intention not to pay the expense (the
      "Unpaid
      Expense").

    

    4.5.2 In
      such
      event, Hadasit shall have the right (but not the obligation) to pay the Unpaid
      Expenses, instead of Rosetta, provided that it has given Rosetta reasonable
      prior written notice to Rosetta of its intent to do so.

    

    4.5.3 In
      the
      event that Hadasit pays the Unpaid Expenses instead of Rosetta within sixty
      (60)
      days of the date of receipt of notice from Rosetta: (i) Hadasit shall take
      the
      control of the prosecution of the Joint Patent in the specific registry of
      the
      specific file or jurisdiction for which the Unpaid Expenses were paid; (ii)
      Rosetta shall assign all of its rights, title and interest in the Joint Patent
      registered in such specific file or jurisdiction to Hadasit, within 30 days
      of a
      written request by Hadasit, following payment of the Unpaid Expenses by Hadasit.
      Nothing contained in sections 4.5.2 and 4.5.3 shall affect, in any way, any
      rights of Rosetta under this Agreement, including rights pertaining to the
      License under Section 7 below.

    

    4.5.4 In
      the
      event that Hadasit has not paid the Unpaid Expenses instead of Rosetta, Rosetta
      may, at any time, in its sole discretion, pay such Unpaid Expenses. In such
      event, Rosetta shall notify Hadasit of its intent to do so, and sections 4.3
      and
      4.4 shall apply accordingly.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    4.6 Hasdasit,
      HUH and their relevant personal, including but not limited to the Principal
      Investigator, shall reasonably cooperate and assist Rosetta and its patent
      attorney, as shall be required in order to facilitate the prosecution and
      maintenance of any Joint Patent. Such assistance will include, but shall not
      be
      limited to signature on any formal document or form which shall require
      Hadasit's, HUH's or the Principal Investigator's signature for the purpose
      of
      filing or maintaining any Joint Patent.

    

    4.7 If
      so
      requested, Rosetta shall consult with Hadasit and its designated patent experts
      with respect to the prosecution and maintenance of Joint Patents. If the event
      described in Section 4.5.3 above occurs and Hadasit assumes control of the
      prosecution of a specific Joint Patent in a specific file or jurisdiction,
      if so
      requested Hadasit will consult with the patent experts of Rosetta with respect
      to the prosecution and maintenance of such specific Joint Patent in such
      specific file or jurisdiction.

    

    5. 
Protective
      Actions

    

    5.1 Each
      party shall promptly notify the other party in writing of any infringement
      of
      purported or threatened infringement of a Joint Patent that may adversely impact
      the rights of the parties hereunder, of which it becomes aware ("Infringement").

    

    5.2 In
      any
      event of any Infringement, Rosetta shall be entitled, at its sole discretion,
      to
      institute an infringement suit or take any other appropriate legal action
      against any person or entity directly or contributorily infringing any Joint
      Patent ("Protective
      Action").
      Prior
      to taking any Protective Action Rosetta will notify Hadasit of the Protective
      Action it intends to take and consider Hadasit's advice regarding such
      contemplated Protective Action. Such actions will be taken by legal counsel
      (the
      "Legal
      Counsel")
      chosen
      by Rosetta for such purpose at its sole expense. In the event Hadasit is
      included as a party to such Protective Action, the Legal Counsel will be
      instructed to provide Hadasit with copies of any official letter, suit or other
      document it intends to send or file on the parties' behalf, within a reasonable
      time prior to sending or filing the same, and to consider any advice of Hadasit
      with respect to any such Protective Action.

    

    5.3 In
      the
      event that Rosetta does not institute Protective Action in response to an
      Infringement within 90 days of the date on which it becomes aware of such
      Infringement, Hadasit shall have the right, but not the obligation, following
      30
      days' prior written notice to Rosetta, to institute such suit Protective Action
      in its own name.

    

    5.4 Regardless
      of which party brings the action, the other party hereby agrees to cooperate
      reasonably in any such effort, including if required in order to facilitate
      a
      Protective Action, the furnishing of a power of attorney (and in such event,
      neither party shall refuse to be included as a party to such legal
      action).

    

    5.5 Any
      recovery obtained by settlement or otherwise as a result of a Protective Action
      shall be disbursed as follows: (i) each party shall first recover [***]% of
      the
      amount of any reasonable expenses incurred by it in connection with such action
      (including counsel fees); and (ii) the remaining recovery shall be treated
      as
      Net Revenues and allocated between the parties accordingly.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    5.6 Without
      prejudice to the above, the parties will reasonably cooperate with respect
      to
      any future legal claims related to a Joint Patent and neither party shall enter
      into any settlement pertaining to such legal claims that affects the other
      parties' rights or interests without such other parties' written consent, which
      consent shall not be unreasonably withheld.

    

    6. 
Publication

    

    The
      Principal Investigator may publish the Results subject to the following terms
      and conditions:

    

    6.1 A
      manuscript of any paper relating to the Results which the Principal Investigator
      intends to publish (the "Proposed
      Publication")
      will
      be submitted by Hadasit to Rosetta for review sufficiently in advance so that
      Rosetta will be provided with sufficient time, which shall not be more than
      60
      days, to take any action required in order to protect any Intellectual Property
      forming part of such Proposed Publication (the "Publication
      IP").
      If
      requested, the Principal Investigator will delete any information from the
      Proposed Publication that constitutes a trade secret or the disclosure of which
      would otherwise be detrimental to Rosetta.

    

    6.2 The
      parties will discuss in good faith the Proposed Publication and if desired
      will
      seek to protect the Publication IP of the Proposed Publication by filing a
      Joint
      patent (pursuant to the provisions of Section 4 above). The resolution whether
      to file a Joint patent regarding the Publication IP of a specific Proposed
      Publication shall be made within 60 days from the date the manuscript of such
      Proposed Publication is provided to Rosetta (the "Resolution
      Period").
      Such
      Proposed Publication will not be published prior to such resolution or the
      lapse
      of Resolution Period (whichever the earlier).

    

    6.3 In
      the
      event the Parties will resolve to file a Joint Patent or otherwise protect
      a
      Publication IP, within the Resolution Period, the Principal Investigator will
      not publish the Proposed Publication prior to the filing of such Joint Patents.
      Notwithstanding the above, in o event will a proposed publication be postponed
      beyond 30 days after the expiration of the Resolution Period.

    

    7. 
License

    

    7.1 Hadasit
      hereby grants Rosetta an exclusive, perpetual, worldwide, royalty bearing,
      license to exploit, use, conduct further research, develop and commercialize
      the
      Licensed IP or any part thereof in any manner (the "License").
      Rosetta shall be entitled to grant sublicenses with respect to the Licensed
      IP
      and/or to otherwise develop or sell, independently or in collaboration with
      other entities, products, services or any other inventions based on the Licensed
      IP.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    7.2 Subject
      to the provisions of Section 7.5 below, Hadasit shall not be entitled to grant
      any rights or licenses with respect to the Licensed IP to any third party or
      to
      use the Licensed IP itself other than for academic research purposes (provided
      that the results of such additional academic research shall also be considered
      Results for purposes of this Agreement).

    

    7.3 Hadasit
      will promptly provide Rosetta with such reasonable information and documentation
      and shall further execute and deliver, or cause its representatives or employees
      to execute and deliver, all such further documents or instruments, as shall
      be
      reasonable required by Rosetta in order to secure its rights pursuant to the
      License granted hereunder.

    

    7.4 The
      exclusivity of the License with respect to specific Results or Joint Patents
      may
      be revoked by Hadasit in the event that Rosetta fails to commercialize the
      Results or Joint Patent within a period of ten (10) years of latter of the
      date
      on which: (i) full and final Results were presented to Rosetta, or (ii) the
      Joint patents are filed. Upon revocation of the License by Hadasit, either
      party
      shall be entitled to license or dispose of its interest in the Joint Patents
      in
      any manner it sees fit without obligation to the other party.

    

    7.5 Without
      derogating from the above, in the event that at the end of seven (7) years
      following the Relevant Date, Rosetta or its affiliates shall not present
      reasonable evidence that it is in the process of negotiating a commercial
      transaction relating to the Results or the Joint Patents ("Commercialization
      Activity"),
      Rosetta shall be obliged to pay Hadasit non-refundable advance payments (the
      "Advance
      Payments",
      which
      shall be creditable against Rosetta's royalty obligations under this Agreement),
      on account of future Royalties (as defined below), as a condition for
      maintaining the exclusivity of the License during the period starting seven
      (7)
      years after the Relevant Date and until Rosetta or its affiliated demonstrates
      Commercialization Activity (the "Relevant
      Period"),
      as
      follows: (i) for the first twelve months of the Relevant Period (to the extent
      applicable) - US$ [***]; (ii) for the second twelve months of the Relevant
      Period (to the extent applicable) - US$ [***]; and (iii) for the third twelve
      months of the Relevant Period (to the extent applicable) - US$ [***]. The
      Advance Payments will be payable in quarterly installments, during each 12-month
      extension period. To the extent that Commercialization Activity is demonstrated
      during any of the 12 month extension period, no further installments shall
      be
      payable.

    

    8. 
Consideration

    

    8.1 In
      consideration for the License and any other services and obligations to be
      performed by or on behalf of Hadasit, HUH or the Principal Investigator with
      respect to the Research, Rosetta shall pay Hadasit royalties (the "Royalties")
      out of
      any Net Revenues which Rosetta or its Affiliates will actually obtain from
      commercialization of the Results or the Joint Patents, as follows:

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    8.1.1 In
      the
      event that Hadasit and the Principal Investigator complete the Research in
      accordance with the Agreement and the Research does not yield any Joint Patents
      but does yield Results that are identifiable and of value, Hadasit shall be
      entitled to Royalties equal to [***]% of the Net Revenues (the "Basic
      Royalties").

    

    8.1.2 In
      the
      event that Hadasit and the Principal Investigator complete the Research in
      accordance with this Agreement and the Research yields Joint Patents, Hadasit
      shall be entitled to:

    

    8.1.2.1 Royalties
      equal to [***]% of Net Revenues actually obtained by Rosetta from
      Commercialization of any specific Results identifiable and of value which were
      not registered as a Joint Patent; or

    

    8.1.2.2 Royalties
      equal to [***]% of Net Revenues actually obtained by Rosetta from
      commercialization of any specific Joint Patent (i.e. the maximal Royalties
      from
      Net Revenues shall be [***]%);

    

    8.1.3 In
      any
      other event, including an event of no Results suitable for commercialization
      or
      an event of a breach of this Agreement by Hadasit, Hadasit shall not be entitled
      to any consideration from Rosetta, including Royalties.

    

    8.2 Notwithstanding
      anything to the contrary set forth herein, in the event that Rosetta or an
      Affiliate of Rosetta must, in its reasonable judgment, make payments to one
      or
      more third parties to obtain a third party license from such third party(ies)
      in
      order to use the Results or Joint Patents or any portion thereof or due to
      any
      infringement of the Licensed IP of such third party rights, Rosetta may offset
      such third-party payments against payments due to Hadasit pursuant to this
      Section 8, provided that the amount payable by Rosetta to Hadasit shall in
      no
      event be reduced pursuant to this clause to an amount which is less than [***]
      percent ([***]%) of the amount that would otherwise have been due to Hadasit
      without the operation of this clause.

    

    8.3 Notwithstanding
      anything to the contrary set forth herein, payments due to Hadasit pursuant
      to
      Section 8.1.2.2 shall continue to be due, on a country by country and product
      by
      product basis, only during the term of a valid claim under a Joint Patent
      covering such product in such country and until the expiration, termination,
      withdrawal, cancellation or disclaiming of the last valid claim under a Joint
      Patent covering such product in such country, after which Royalties shall
      continue to be payable under Section 8.1.1 or 8.1.2.1 until the termination
      of
      this Agreement.

    

    8.4 Within
      thirty (30) days following the end of each calendar quarter during the Term
      (as
      defined below), Rosetta shall: (i) provide Hadasit with a written report which
      will specify the calculation of the Revenues accumulated by Rosetta with respect
      to the Results or Joint Patents in such then-completed calendar quarter and
      the
      Royalties payable to Hadasit under the terms of Section 8.1 above (the
      "Quarterly Royalties Amount"); and (ii) pay Hadasit the Quarterly Royalties
      Amount by way of bank wire transfer to such account as Hadasit shall advise
      Rosetta in writing.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    8.5 In
      the
      event that VAT will be duly required with respect to any Royalties which may
      be
      paid hereunder, the VAT will be added by Rosetta to the Quarterly Royalties
      Amount against receipt of a proper tax invoice from Hadasit.

    

    8.6 Rosetta
      shall maintain complete and accurate records of Net Revenues and any amounts
      payable to Hadasit in relation to same. Rosetta shall retain such records
      relating to a given Calendar Quarter for at least three (3) years after the
      conclusion of that Calendar Quarter. During such three (3) year period, Hadasit
      shall have the right, at Hadasit's expense, to cause an independent,
      nationally-recognized, certified public accountant reasonably acceptable to
      Rosetta, who is bound by a suitable confidentiality arrangement with Rosetta,
      to
      inspect Rosetta's and the relevant Affiliates' records relating to Net Revenues
      during normal business hours for the sole purpose of verifying any reports
      and
      payments delivered under this Agreement. Such public accountant will only repot
      to Hadasit whether or not Rosetta is in compliance with its obligations under
      this Agreement and shall not disclose or report to Hadasit any other information
      or data to which it has access as part of this examination. The parties shall
      reconcile any underpayment o overpayment within thirty (30) days after the
      accountant delivers the results of the audit. Hadasit may exercise its rights
      under this Section 8.6 only once every year and only with thirty (30) days
      prior
      notice to Rosetta. Notwithstanding the aforesaid, in the event that any
      inspection as aforesaid reveals any underpayment by Rosetta to Hadasit in
      respect of any year in an amount exceeding [***]% ([***] percent) of the amount
      actually paid by Rosetta to Hadasit in respect of such year, then Rosetta shall
      (in addition to paying Hadasit the shortfall), bear the costs of such
      inspection.

    

    8.7 For
      the
      purpose of sharing a portion of the costs Hadasit shall incur in the performance
      of its obligations under this Agreement with respect of Research, Rosetta shall
      pay Hadasit as follows (the "Research
      Payment(s)"):

    

    8.7.1 An
      initial Research Payment in the amount of US $10,000 shall be paid by Rosetta
      to
      Hadasit within five business days of the execution of this
      Agreement.

    

    8.7.2 An
      additional US $10,000 will be paid by Roetta to Hadasit one month after the
      payment referred to in Section 8.7.1.

    

    8.7.3 Hadasit
      shall use its best efforts to obtain external funding for the Research in form
      of or as part of a research grant in accordance with relevant industry standards
      (the "Grant").
      For
      this purpose, Hadasit shall apply to certain reputable research institutions
      as
      shall be agreed between the parties. The terms of the Grant shall not derogate
      from any of Rosetta's rights under this Agreement, unless otherwise agreed
      between the parties in advance and in writing. When the Grant is received by
      Hadasit, Hadasit shall repay to Rosetta the amounts paid under Section 8.7.1
      and
      8.7.2 above (the "Repaid
      Amounts"),
      without interest, provided that the terms of such Grant shall not prevent such
      repayment to Rosetta. In the event that the Grant shall be in an amount less
      than US$ [***], than Hadasit shall deduct an amount of US$ [***] from the Repaid
      Amounts paid to Rosetta.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    8.7.4 In
      the
      event that Hadasit does not succeed in obtaining the Grant within a period
      of 12
      months following the Effective Date, then, subject to the continued performance
      by Hadasit of the Research and the fulfillment of all Hadasit's obligations
      under this Agreement, Rosetta shall pay Hadasit additional Research Payment
      in
      the amount of US $42,500, payable in three equal monthly
      installments.

    

    8.8 Any
      amount payable hereunder which has not been made upon its due date of payment,
      shall bear interest from the date such payment is due until the date of its
      actual payment, at the maximum interest charged by Bank Leumi Le Israel B.M.
      for
      unapproved overdrafts.

    

    9. 
Indemnification

    

    9.1 Each
      party hereby disclaims any representations or warranties in respect of the
      Research, the Results, the Joint Patents and any related patents, their
      potential use, exploitability or that they do not infringe third party
      rights.

    

    9.2 Rosetta
      shall indemnify and hold Hadasit, the HUH, the HMO and any of their employees,
      (the "Indemnitees"),
      harmless against and from any claim, damage or expense of any kind resulting
      from any use by Rosetta, or those authorized by it, will make of the Results
      or
      the Joint Patents (if any), provided that Hadasit will comply with the following
      terms:

    

    9.2.1 Hadasit
      shall: (i) notify Rosetta in writing of any claim or action triggering an
      indemnification obligation under this Section 9.2 promptly after it becomes
      aware of the same; and (ii) provide Rosetta with such information and assistance
      as reasonably required in connection therewith; and (iii) enable Rosetta, at
      its
      request, to participate in and/or control any proceedings or negotiations
      related to such defense or settlement with its own counsel.

    

    9.2.2 Under
      no
      circumstance shall the Indemnitees Hadasit compromise any asserted liability
      hereunder without the prior written consent of Rosetta.

    

    9.2.3 Such
      indemnity shall not apply to claims made by third parties that the Results
      or
      Joint Patents infringe such third party's intellectual property
      rights.

    

    9.3 Neither
      party shall be liable (whether under contract, tort (including negligence or
      otherwise) to the other party, or any third party for any indirect, incidental
      or consequential damages, including, without limitation, any loss or damage
      to
      business earnings, lost profits or goodwill and lost or damaged data or
      documentation, suffered by any person, arising from and/or related with and/or
      connected to this agreement even if such party is advised of the possibility
      of
      such damages.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    10. 
Confidentiality

    

    10.1 Rosetta,
      Hadasit and the Principal Investigator have previously signed and executed
      a
      non-disclosure agreement, in the form as Annex
      C
      hereto,
      which forms an integral part of this Agreement (the "NDA").

    

    10.2 It
      is
      recorded and agreed that Rosetta shall be entitled to disclose this Agreement,
      the Results and any other information relating to the Research and the Licensed
      IP, as shall be reasonably required in the scope of business, to enable a third
      party to perform technological due diligence examinations relating to
      contemplated transactions of Rosetta, in the course of Rosetta's
      commercialization efforts or as shall otherwise be required in order to utilize
      the License, as well as to its consultants and advisors (on an as-needed basis),
      provided that such third parties will be subject to a confidentiality
      undertaking not less stringent that the obligation set forth
      herein.

    

    11. 
Term
      and Termination

    

    11.1 The
      term
      of this Agreement, including the License granted hereunder, shall commence
      upon
      the Effective Date and shall terminate on the date on which all of the Joint
      Patents which may be registered under the terms set forth herein shall have
      expired (the "Term").

    

    11.2 If
      the
      Research does not produce any Joint Patents or Research Results with independent
      commercial value, then Rosetta may terminate this Agreement upon sixty (60)
      days
      notice to Hadasit. In addition, in the event that either party commits a
      material breach of its obligations under this Agreement and fails to cure that
      breach (where the breach is capable of cure) within sixty (60) days after
      receiving written notice thereof, the non-breaching party may terminate this
      Agreement immediately upon written notice.

    

    12. 
Force
      Majeure

    

    Neither
      party shall be responsible or liable for any delay or failure in performance
      under this Agreement arising as a result of any occurrence or contingency beyond
      its reasonable control, including but not limited to, accident, act of God,
      acts
      of the public enemy, earthquake, fire, flood, explosion, strikes, riots, civil
      commotion, war (declared or not), requirements or acts of any government or
      agency thereof and judicial action. The delayed party shall send written notice
      of the delay and the reason therefor to the other party as soon as possible
      after the party delayed knew of the cause of delay in question.

    

    13. 
Miscellaneous

    

    13.1 Assignment.
      No
      party to this Agreement shall be entitled to transfer or assign its rights
      or
      obligations under this Agreement, unless with the prior written consent of
      the
      other party, which shall not be unreasonably withheld; provided however that
      an
      assignment resulting from merger and/or acquisition of either party or a sale
      of
      the assets that are the subject of this Agreement shall not require the consent
      of the other party, in the event that the surviving entity is committed to
      such
      assigning party's obligations hereunder.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        14

        
          

        

      

      
        
        

      

    

    13.2 No
      Agency.
      It is
      hereby expressly declared and agreed that this Agreement in no way establishes
      any principal-agent, employer-employee, or partnership relations between the
      parties. Nothing in this Agreement shall be construed as granting either party
      the power or authority to act for or on behalf of the other party, to create
      any
      undertakings on behalf of the other party, or to bind or commit the other party
      in respect to any such undertakings, except as set forth herein or as otherwise
      agreed to in writing between the parties prior to such act.

    

    13.3 Law.
      This
      Agreement shall be governed by the laws of the State of Israel.

    

    13.4 Mediation
      & Arbitration.
      The
      parties shall endeavor to equitably settle any dispute which may arise between
      them under or in connection to this Agreement (a "Dispute").
      Any
      Dispute arising between the parties not amicably resolved within 15 (fifteen)
      days, shall be referred to independent mediation (the "Mediation")
      by a
      qualified person appointed by the parties for such purposes and failing
      agreement between them within a thirty day period, by the legal counsel of
      Rosetta and Hadasit, upon the written request of any of the parties (with a
      copy
      to the other party) (the "Mediator").
      the
      Mediation shall be held in accordance with the provisions of Article 79C of
      the
      Courts Law - 1984. The Mediator shall try to resolve the Dispute by unanimous
      consent of the parties within additional 30 days and in the event the Mediator
      shall fail t do so the Dispute will be referred to an arbitration (the
      "Arbitration"),
      which
      will be conducted by the Mediator, who will serve as the arbitrator in such
      event. The Arbitrator shall be bound to reason his final resolution in the
      Arbitration and the Arbitration shall be subject to the substantive law (but
      not
      to rules of procedure and evidence).

    

    13.5 Entire
      Agreement.
      This
      Agreement, including all annexes attached hereto constitutes the entire
      understanding of the parties and supersedes all oral or written representations
      or agreements, privileges or understandings between the parties, including
      but
      not limited to the Joint Research Memorandum, all of which shall become, upon
      signature of this Agreement, null and void.

    

    13.6 Amendment.
      No
      modification or amendment of this Agreement may be made except in a written
      instrument duly signed by all parties.

    

    13.7 Severability.
      If any
      non-material condition, term or covenant of this Agreement shall at any time
      be
      held to be void, invalid or unenforceable such condition, covenant or term
      shall
      be construed as severable and such holding shall attach only to such condition,
      covenant or term and shall not in any way affect or render void, invalid or
      unenforceable any other condition, covenant or term of this Agreement, and
      this
      Agreement shall be carried out as if such void, invalid or unenforceable term
      were not embodied herein.

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        15

        
          

        

      

      
        
        

      

    

    13.8 Waivers.
      The
      failure at any time of either Party to enforce any of the terms or conditions
      or
      any right or to exercise any option of this Agreement will in no way be
      construed to be a waiver of such terms, conditions, rights or options, or in
      any
      way to affect the validity of this Agreement. A waiver by a party of any of
      its
      rights under this Agreement shall not be effective unless made by a written
      instrument duly signed by such party, and shall not be deemed a waiver of any
      other right hereunder.

    

    13.9 Costs.
      Each
      party shall bear its own costs and expenses in connection with the negotiations
      and signature of this Agreement, including taxes. Stamp tax, if required, shall
      be shared equally by the parties.

    

    13.10 Notices.
      Any
      notice sent by one party to the others to the addresses set forth below shall
      be
      considered as having reached its destination, if it was delivered by hand,
      at
      the time of its delivery; if it was sent by registered mail, within 96 hours
      from the time it was so dispatched; and if it was sent by facsimile, within
      48
      hours from the receipt of the confirmation of proper transmission of the
      notice.

    

     

    
      	
              If
                to Rosetta:

            	
              10
                Plaut Street, Rehovot 76706, Israel

            
	 	
              Fax:
                972-8-9484766

            
	 	 
	
              If
                to Hadasit:

            	
              POB
                12000, Jerusalem 91120, Israel

            
	 	
              Fax:
                +972-2-643-7712

            
	 	
              Attention:
                CEO, Copy: Legal Counsel

            

    

    

    13.11 Notwithstanding
      anything to the contrary herein, Rosetta shall not use the names and/or logos
      of
      Hadasit and/or the HUH, and shall not disclose their involvement in the Research
      without both their prior written approval, all except for (a) references to
      scientific publications which are already in the public domain at the time
      of
      executing this Agreement and (b) applications for regulatory approvals to
      official authorities, and (c) as requested by regulatory authorities as required
      by law or applicable regulation. Subject to the foregoing, Rosetta shall include
      appropriate acknowledgement and credit to the HMO and their employees in any
      publication relating to the Research in whatever media, including application(s)
      to official authorities or presentations to potential
      investors.

    

    IN
      WITNESS WHEREOF, the Parties have set their signatures hereunto as of the date
      first above written.

    

    
      	
              HADASIT
                RESEARCH SERVICES AND

            	 	
              ROSETTA
                GENOMICS LTD.

            
	
              DEVELOPMENT
                LTD.

            	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	
              BY:

            	
            	 	
              By:

            	
            
	 	 	 	 	 
	
              Name:

            	
            	 	
              Name:

            	
            
	 	 	 	 	 
	
              Title:

            	
            	 	
              Title

            	
            

    

    

    

    As
      to the
      obligations imposed on the 

    Principal
      Investigator:

    

    

    ______________________________

    Prof.
      Eithan Galum

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        16The
      Rockefeller University

     

    License
      Agreement

     

    This
      Agreement (this “Agreement”)
      is
      between The Rockefeller University, a New York nonprofit corporation
      (“Rockefeller”), and Rosetta Genomics Ltd., an Israeli corporation
      (“Company”).
      This
      Agreement will become effective on May 4, 2006 (the “Effective
      Date”).

     

    BACKGROUND

     

    Rockefeller
      owns certain intellectual property developed by Dr. Thomas Tuschl and his
      colleagues relating to micro RNA sequences. Rockefeller also owns certain
      applications for United States letters patent relating to the intellectual
      property. Company desires to obtain a co-exclusive license under the patent
      rights to exploit the intellectual property. Rockefeller has determined that
      the
      exploitation of the intellectual property by Company is in the best interest
      of
      Rockefeller and is consistent with its educational and research missions and
      goal.

     

    In
      consideration of the mutual obligations contained in this Agreement, and
      intending to be legally bound, the parties agree as follows:

     

    1.  LICENSE

     

    1.1  License
      Grant.
      Rockefeller grants to Company and its Affiliates a co-exclusive, as set forth
      in
      Section 1.3, world-wide license (the “License”)
      to
      make, have made, use, have used, import, sell, have sold and offer for sale
      and
      have offered for sale Licensed Products in the Field of Use during the Term
      (as
      such terms may be defined in Sections 1.2 and 6.1). Licensee has no right to
      sublicense except as set forth in Section 1.5. Rockefeller grants no other
      rights or licenses. 

     

    1.2  Related
      Definitions.
      The
      term “Affiliate”
      means
      a
      legal entity that is controlling, controlled by or under common control with
      Company and that has executed either this Agreement or a written Joinder
      Agreement agreeing to be bound by all of the terms and conditions of this
      Agreement. For purposes of this Section 1.2, the word “control”
means
      (x) the direct or indirect ownership of more than fifty percent (50%) of the
      outstanding voting securities of a legal entity, (y) the right to receive fifty
      percent (50%) or more of the profits or earnings of a legal entity, or (z)
      the
      right to determine the policy decisions of a legal entity. 

     

    The
      term
“Licensee”
means
      Company and its Affiliates.

     

    The
      term
“Licensed
      Products”
means
      products that are made, made for, used, imported, sold or offered for sale
      by
      Licensee and its sublicensees and that either (i) in the absence of this
      Agreement, would infringe at least one Valid Claim of the Rockefeller Patent
      Rights, (ii) use a process or machine covered by a Valid Claim of Rockefeller
      Patent Rights, or (iii) use, at least in part, any Rockefeller Technical
      Information covered by a Valid Claim of Rockefeller Patent Rights.

     

    The
      term
“Rockefeller
      Patent Rights”
means
      all patent rights represented by or issuing from: (a) the United States patent
      applications listed in Exhibit A; (b) any continuation, divisional and re-issue
      applications of (a); and (c) any foreign counterparts and extensions of (a)
      or
      (b). 

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    The
      term
“Rockefeller
      Technical Information”
means
      all the information contained in the patents and the patent applications listed
      in Exhibit A and any other technical information disclosed or referenced in
      Exhibit A.

     

    The
      term
“Field
      Of Use”
means
      Diagnosis of any disease or condition in humans.
      Specifically excluded from the Field of Use is any use for therapeutic purposes,
      whether said use is in vivo or in vitro. For clarity, ASR (Analyte Specific
      Reagent) products are included in the Field of Use.

     

    The
      term
“Valid
      Claim” means
      a
      claim in a pending or an issued, unexpired patent within the Rockefeller Patent
      Rights that (a) has not been finally cancelled, withdrawn, abandoned or rejected
      by any administrative agency or other body of competent jurisdiction, (b) has
      not been revoked, held invalid, or declared unpatentable or unenforceable in
      a
      decision of a court or other body of competent jurisdiction that is unappealable
      or unappealed within the time allowed for appeal, (c) has not been rendered
      unenforceable through disclaimer or otherwise, and (d) is not lost through
      an
      interference proceeding, provided, however, that any claim that has been pending
      for more than five (5) years after Company requests in writing that Rockefeller
      actively prosecute such claim (in the case of a claim to a specific micro RNA
      sequence by filing a divisional application specific to such sequence) shall
      cease to be a Valid Claim unless and until such claim is issued. 

     

    The
      term
“Diagnosis”
      means
      (a) the determination of (i) the presence of a disease, (ii) the stage,
      progression or severity of a disease, (iii) the risk of contracting a disease,
      or (iv) the effect on a disease of a particular treatment; and/or (b) the
      selection of patients for a particular treatment with respect to a
      disease.

     

    1.3  Reservation
      of Rights by Rockefeller.
      Rockefeller reserves the right to use, and to permit other entities to use,
      the
      Rockefeller Patent Rights for all purposes, provided however, that Rockefeller
      will not grant more than three (3) licenses (“Other Licenses”) to third parties
      to make, have made, use, have used, import, sell, have sold or offer for sale
      and have offered for sale Licensed Products in the Field of Use during the
      Term.

     

    1.4  U.S.
      Government Rights.
      The
      parties acknowledge that the United States government retains rights in
      intellectual property funded under any grant or similar contract with a Federal
      agency. The License is expressly subject to all applicable United States
      government rights, including, but not limited to, any applicable requirement
      that products, which result from such intellectual property and are sold in
      the
      United States, must be substantially manufactured in the United States. At
      the
      request of Company, and at Company’s expense, Rockefeller will assist Company in
      an effort to obtain a waiver of such requirement.

     

    1.5  Sublicenses.
      Licensee
      shall have no right to grant sublicenses under the license granted herein,
      unless such sublicense is granted as part of a license along with other
      substantial technology or patent rights of Licensee. Any such sublicense will
      be
      subject to each of the following conditions:

     

    (a)  In
      each
      sublicense agreement, Licensee will, (i) prohibit the sublicensee from further
      sublicensing, except for a further sublicense limited to the right to
      manufacture and distribute a Licensed Product developed by the sublicensee,
      and
      (ii) require the sublicensee to comply with the terms and conditions of this
      Agreement other than the payment and reporting obligations of
      Company.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    (b)  Within
      thirty (30) days after Licensee enters into a sublicense agreement, Company
      will
      deliver to Rockefeller a complete and accurate copy of the entire sublicense
      agreement written in the English language. Rockefeller’s receipt of the
      sublicense agreement, however, will constitute neither an approval of the
      sublicense nor a waiver of any right of Rockefeller or obligation of Company
      under this Agreement.

     

    (c)  In
      the
      event that Company causes or experiences a bankruptcy event, all payments due
      to
      Company from its Affiliates or sublicensees under the sublicense agreement
      will,
      upon notice from Rockefeller to such Affiliate or sublicensee, become payable
      directly to Rockefeller for the account of Company. Upon receipt of any such
      funds, Rockefeller will remit to Company the amount by which such payments
      exceed the amounts owed by Company to Rockefeller. 

     

    (d)  Company’s
      execution of a sublicense agreement will not relieve Company of any of its
      obligations under this Agreement. Company is primarily liable to Rockefeller
      for
      any act or omission of an Affiliate or sublicensee of Company that would be
      a
      breach of this Agreement if performed or omitted by Company, and Company will
      be
      deemed to be in breach of this Agreement as a result of such act or omission.
      

     

    2.  FEES
      AND ROYALTIES

     

    2.1  License
      Initiation Fee.
      In
      partial consideration of the License, Company will pay to Rockefeller on the
      Effective Date a non-refundable license initiation fee of Sixty
      Thousand Dollars ($60,000). 

     

    2.2  License
      Maintenance Fees.
      In
      partial consideration of the License, Company will pay to Rockefeller, on each
      anniversary of the Effective Date, a license maintenance fee of [***] Dollars
      ($[***]). 

     

    2.3  Progress
      Report.
      In
      addition, Company shall provide Rockefeller on each anniversary of the Effective
      Date with written progress reports discussing the development, evaluation,
      testing and commercialization of all Licensed Products.

     

    2.4  Earned
      Royalties.
      In
      partial consideration of the License, subject to Sections 2.5 and 2.6, Company
      will pay to Rockefeller a royalty of (i) [***] Percent ([***]%) of Net Sales
      by
      Company and its Affiliates, and (ii) [***] Percent ([***]%) of all royalties
      received by the Company from sublicensees with respect to sales of Licensed
      Products, during each Quarter. 

     

    The
      term
“Quarter”
means
      each three-month period beginning on January 1, April 1, July 1 and October
      1.

     

    The
      term
“Net
      Sales”
means
      the consideration received from, or fair market value attributable to, each
      Sale, less Qualifying Costs directly attributable to a Sale and actually
      identified on the invoice and borne by Licensee or its sublicensees. Net sales
      shall not include sales or transfers between Company and its Affiliates, unless
      the Licensed Product is consumed by the Affiliate. For purposes of determining
      Net Sales, the words “fair market value” mean the cash consideration that
      Licensee or its sublicensees would realize from an unrelated buyer in an arms
      length sale of an identical item sold in the same quantity and at the time
      and
      place of the transaction. 

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    The
      term
“Sale”
means
      any bona fide transaction by Licensee or its sublicensees for which
      consideration is received or expected from an unaffiliated third party for
      the
      sale, use, lease, transfer or other disposition of a Licensed Product, and
      a
      Sale is deemed completed at the time that Licensee or its sublicensees invoices,
      ships or receives payment for a Licensed Product, whichever occurs
      first.

     

    The
      term
“Qualifying
      Costs”
means:
      (a) customary discounts in the trade for quantity purchased, prompt payment
      or
      wholesalers and distributors; (b) rebates (including Medicare and similar types
      of rebates), credits or refunds for claims or returns that do not exceed the
      original invoice amount; (c) prepaid outbound transportation expenses and
      transportation insurance premiums; and (d) sales and use taxes and other fees
      imposed by a governmental agency. 

     

    2.5  Stacking
      Protection.
      If
      Licensee becomes obligated to pay royalties to third parties for technology
      necessary to develop or manufacture a Licensed Product, then the royalty rate
      payable to Rockefeller under Section 2.4 for such Licensed Product will be
      reduced pro rata with respect to all third party royalty rates, so as to reduce
      the maximum aggregate royalty rate to [***]percent ([***]%). A reduction of
      the
      royalty rate in Section 2.4 for one Licensed Product will not affect the royalty
      rate for another Licensed Product. 

     

    2.6  Payments
      Related to Combination Products.
      In the
      event that a Licensed Product is sold in combination with another product or
      products, which are not a Licensed Products, the amount of royalties and
      payments paid shall be based on the proportion of the value of such combination
      product reasonably attributable to the Licensed Product. In particular, if
      a
      Licensed Product contains or is designed to detect both micro RNA sequences
      covered by a Valid Claim of Rockefeller Patent Rights and micro RNA sequences
      that are not covered by a Valid Claim of Rockefeller Patent Rights, then Net
      Sales of such Licensed Product shall be multiplied by the ratio of (x) the
      number of micro RNA sequences covered by a Valid Claim of Rockefeller Patent
      Rights in a given Licensed Product to (y) the total number of micro RNA
      sequences included in such given Licensed Product to determine the portion
      of
      the value of the micro RNA sequences in the combination product attributable
      to
      Rockefeller micro RNA sequences.

     

    2.7  Royalty
      Floor.
      Notwithstanding Sections 2.5 and 2.6, (i) in no event will the royalty rate
      payable to Rockefeller under Section 2.4 for any Licensed Product sold by
      Licensee be reduced to less than [***] percent ([***]%) of Net Sales, and (ii)
      in no event will the royalty payable to Rockefeller under Section 2.4 for any
      Licensed Product sold by a sublicensee be reduced to less than [***] percent
      ([***]%) of sublicensee Net Sales. 

     

    2.8  Sublicense
      Fees.
      In
      partial consideration of the License, Company will pay to Rockefeller a
      sublicense fee of [***] percent ([***]%) of all payments and the fair market
      value of all other consideration of any kind received by Company from
      sublicensees during the Quarter, other than: (a) equity investments in Company
      by a sublicense up to the amount of the fair market value of the equity
      purchased on the date of the investment; (b) loan proceeds paid to Company
      by a
      sublicensee in an arms length, full recourse debt financing; and (c) sponsored
      research funding paid to Company by a sublicensee in a bona fide transaction.
      Such sublicense fee sharing will be discountable in accordance with Section
      2.6,
      however, in no event will the sublicense fee be reduced to less than [***]
      percent ([***]%) of the consideration received by the Company from the
      sublicensee, except for royalties paid on sublicensee Sales which will be
      subject to the royalty floor in Section 2.7.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    2.9  Most
      Favored Licensee.
      If
      Rockefeller grants a license under the Rockefeller Patent Rights and which
      will
      permit such licensee to manufacture or sell for any use within the scope of
      the
      license granted in this Agreement at a lower royalty rate than that provided
      in
      this Agreement, then Rockefeller will promptly notify Company of such license.
      The notice will include all material terms and conditions of such license,
      including degree of non-exclusivity, duration, field, territory, audit rights,
      all fees, and royalty rates, and extend to Company the lower royalty rates
      along
      with all of the material terms and conditions of such license. In the event
      that
      Company elects to take the royalty rates and the material terms and conditions
      of such noticed license, the royalty rate and all material terms and conditions
      of such noticed license shall apply to Company upon the date Company provides
      Rockefeller with its written notice of such election.

     

    3.  REPORTS
      AND PAYMENTS

     

    3.1  Royalty
      Reports.
      Within
      sixty (60) days after the end of each Quarter following first commercial Sale
      of
      a Licensed Product, Company will deliver to Rockefeller a report, certified
      by
      the chief financial officer of company, detailing the calculation of all
      royalties and fees due to Rockefeller for such Quarter. The report will include,
      at a minimum: (a) the number of Licensed Products involved in Sales, listed
      by
      product, by country; (b) gross consideration invoiced, billed or received for
      Sales in the Quarter; (c) Qualifying Costs, listed by category of cost; (d)
      Net
      Sales, listed by product, by country; (e) royalties and fees owed to
      Rockefeller, listed by category, by product, by country; and (f) any applicable
      credits resulting from royalty credits.

     

    3.2  Payments.
      Company
      will pay all royalties due to Rockefeller under Section 2.4 within forty-five
      (45) days after the end of the Quarter in which the royalties or fees
      accrue.

     

    3.3  Records.
      Company
      will maintain, and cause its Affiliates and sublicensees to maintain, complete
      and accurate books and records to verify Sales, Net Sales, and all of the
      royalties, fees and other payments made under this Agreement. The records for
      each Quarter will be maintained for at least five (5) years after submission
      of
      the applicable report required under Section 3.1.

     

    3.4  Audit
      Rights.
      Upon
      reasonable prior written notice to Company, Company will provide an accountant
      selected by Rockefeller and approved by Company, such approval not to be
      unreasonably withheld, with access to all of the books and records required
      by
      Section 3.3 to conduct a review or audit of Sales, net Sales, Qualifying Costs
      (including the method of determining Qualifying Costs) and all of the royalties,
      fees, and other payments payable under this Agreement. Access will be made
      available: (a) during normal business hours; (b) in a manner reasonably designed
      to facilitate review or audit without unreasonable disruption to Company’s
      business; and (c) no more than once each calendar year during the Term and
      for a
      period of five (5) years thereafter. Company will promptly pay to Rockefeller
      the amount of any underpayment determined by the review or audit plus accrued
      interest. If the review or audit determines that Company has underpaid any
      royalty payment by [***] ([***]%) or more, then Company will also promptly
      pay
      the costs and expenses of Rockefeller and its accountants in connection with
      the
      review or audit.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    3.5  Information
      Rights.
      After
      the closing of the Company’s IPO, Company will provide to Rockefeller a copy of
      each annual report, proxy statement, 10-K, 10-Q and other material reports
      filed
      with the U.S. Securities and Exchange Commission.

     

    3.6  Currency.
      All
      dollar amounts referred to in this Agreement are expressed in United States
      dollars. All payments will be made in United States dollars. If Licensee
      receives payment from a third party in a currency other than United States
      dollars for which a royalty or fee is owed under this Agreement, then (a) the
      payment will be converted into United States dollars at the conversion rate
      for
      the foreign currency as published in the eastern edition of the Wall Street
      Journal as of the last business day of the Quarter in which the payment was
      received by Licensee, and (b) the conversion computation will be documented
      by
      Company in the applicable report delivered to Rockefeller under Section
      3.1.

     

    3.7  Place
      of Payment.
      All
      payments by Company are payable to “The Rockefeller University” and will be made
      to the following addresses:

     

    
      	
              By
                Electronic Transfer:

               

            	
              By
                Check:

               

            
	
              JP
                Morgan Chase Bank

            	
              The
                Rockefeller University

            
	
              1166
                Avenue of the Americas, 16th Floor

            	
              Office
                of Technology Transfer

            
	
              New
                York, NY 10036

            	
              502
                Founders Hall

            
	
              Swift
                Code: CHASUS33

            	
              1230
                York Avenue

            
	
              Account
                #134-756355

            	
              New
                York, NY 10021

            
	
              Reference:
                Technology Transfer/212-327-7116

            	 

    

     

    3.8  Interest.
      All
      amounts that are not paid by Company when due will accrue interest from the
      date
      due until paid at a rate equal to one percent (1.0%) per month (or the maximum
      allowed by law, if less).

     

    4.  CONFIDENTIALITY
      AND USE OF ROCKEFELLER’S
      NAME

     

    4.1  Rockefeller’s
      Confidential Information.
      The
      term “Confidential
      Information”
      includes all technical information, inventions, developments, discoveries,
      software, know-how, methods, techniques, formulae, data, processes and other
      proprietary ideas, whether or not patentable, that Rockefeller identifies as
      confidential or proprietary at the time it is delivered or communicated to
      Licensee or its sublicensees.

     

    4.2  Licensee’s
      Obligation.
      Licensee will maintain in confidence and not disclose to any third party any
      Confidential Information. Licensee will use the Confidential Information only
      for the purposes of this Agreement. Licensee will ensure that Licensee’s
      employees have access to the Confidential Information only on a need to know
      basis and are obligated in writing to abide by Licensee’s obligations under this
      Agreement. The obligations under this Section 4.2 will not apply to: (a)
      information that is known to Licensee or independently developed by Licensee
      prior to the time of disclosure, in each case where the Confidential Information
      is a specific micro RNA sequence, to the extent evidenced by written records
      promptly disclosed to Rockefeller upon receipt of the Confidential Information
      and in each other case, to the extent evidenced by written records that Company
      can demonstrate were in existence at the time of receipt of the Confidential
      Information; (b) information that is disclosed to Licensee by a third party
      that
      has a right to make such disclosure; (c) information that becomes patented,
      published or otherwise part of the public domain as a result of acts by
      Rockefeller or a third party obtaining such information as a matter of right;
      or
      (d) information that is required to be disclosed by order of United States
      governmental authority or a court of competent jurisdiction provided that
      Licensee must use its best efforts to obtain confidential treatment of such
      information by such agency or court.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    4.3  Disclaimer.
      Rockefeller is not obligated to accept any confidential information from
      Licensee, except for the reports required by Sections 2.3, 3.1 and 3.5.
      Rockefeller, acting through its Office of Technology Transfer and finance
      offices, will use its best efforts not to disclose to any third party outside
      of
      Rockefeller any confidential information of Licensee contained in those reports,
      subject to exceptions analogous to those contained in Section 4.2(a) - (d)
      above. Rockefeller bears no institutional responsibility for maintaining the
      confidentiality of any other information of Licensee. Licensee may elect to
      enter into confidentiality agreements with individual investigators at
      Rockefeller that comply with Rockefeller’s internal policies.

     

    4.4  Use
      of
      Rockefeller’s Name.
      Licensee, its sublicensees and their employees and agents may not use the name,
      logo, seal, trademark or service mark (including any adaptation of them) of
      Rockefeller or any Rockefeller school, organization, employee, student or
      representative, without the prior written consent of Rockefeller.

     

    5.  TERM
      AND TERMINATION

     

    5.1  Term.
      This
      Agreement will commence on Effective Date and terminate upon the later of:
      (a)
      the expiration or abandonment of the last patent to expire or become abandoned
      of the Rockefeller Patent Rights; or (b) if no patent ever issues from the
      Rockefeller Patent Rights, ten (10) years after the first commercial sale of
      the
      first Licensed Product (as the case may be the “Term”).

     

    5.2  Early
      Termination by Company.
      Company
      may terminate this Agreement at any time upon sixty (60) days prior written
      notice to Rockefeller after completing each of the following: (a) ceasing to
      make, have made use, import, sell and offer for sale all Licensed Products;
      (b)
      terminating all sublicenses and causing all Affiliates and sublicenses to cease
      making, having made, using, importing, selling and offering for sale all
      Licensed Products; and (c) paying all amounts owed to Rockefeller under this
      Agreement through the date of termination.

     

    5.3  Early
      Termination by Rockefeller.
      Rockefeller may terminate this Agreement if: (a) Company is more than thirty
      (30) days late in paying to Rockefeller any amounts owned under this Agreement
      and does not immediately pay Rockefeller in full within ten (10) days after
      demand; or (b) Company or its Affiliates or sublicensees breaches this Agreement
      and does not cure the breach within forty-five (45) days after written notice
      of
      the breach.

     

    5.4  Effect
      of Termination.
      Upon
      the termination of this Agreement for any reason: (a) the License terminates;
      (b) Licensee and its sublicensees will cease all making, having made, using,
      importing, selling and offer for sale all Licensed Products; (c) Company will
      pay to Rockefeller all amounts owned to Rockefeller through the date of
      termination under this Agreement; (d) Licensee will, at Rockefeller’s request,
      return to Rockefeller all Confidential Information; and (e) in the case of
      termination under Section 5.3, all duties of Rockefeller and all rights (but
      not
      duties) of Licensee under this Agreement immediately terminate without further
      action required by either Rockefeller or Licensee.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    5.5  Survival.
      Company’s obligation to pay all amounts owned to Rockefeller under this
      Agreement will survive the termination of this Agreement for any reason.
      Articles 4, 5, 8, 9 and Section 11.10 will survive the termination of this
      Agreement for any reason in accordance with their respective terms.

     

    6.  PATENT
      MAINTENANCE AND REIMBURSEMENT

     

    6.1  Patent
      Maintenance.
      Rockefeller controls the preparation, prosecution and maintenance of the
      Rockefeller Patent Rights and the selection of patent counsel, with input from
      Company. Company will be copied on, and allowed to comment upon, all substantive
      issues in the patent prosecution.

     

    6.2  Patent
      Reimbursement.
      Within
      thirty (30) days after the Effective Date, Company shall reimburse Rockefeller
      $[***] for a pro rata share of patent and licensing costs incurred prior to
      the
      Effective Date. Company shall pay a pro rata share (based on the number of
      licenses granted to the Rockefeller Patent Rights), not to exceed [***]%, for
      all attorney fees, expenses, official fees and other charges incident to the
      preparation, prosecution, and maintenance of such patent applications and
      patents following the Effective Date.

     

    7.  INFRINGEMENT

     

    7.1  Notice.
      Company
      and Rockefeller will notify each other promptly of any infringement of the
      Rockefeller Patent Rights that may come to their attention. Company and
      Rockefeller will consult each other in a timely manner concerning any
      appropriate response to the infringement.

     

    7.2  Prosecution.
      Rockefeller may prosecute any infringement of the Rockefeller Patent Rights
      at
      Rockefeller’s expense. If Rockefeller elects to prosecute such infringement,
      then financial recoveries will retained by Rockefeller in their
      entirety.

     

    7.3  Intervention.
      Rockefeller reserves the right to request Company to join in any litigation
      under Section 7.2 If Company elects to participate in any such litigation,
      then
      financial recoveries from any such litigation will be shared between Company
      and
      Rockefeller in proportion with their respective shares of the aggregate
      litigation expenditures.

     

    7.4  Company
      Prosecution.
      If
      Rockefeller does no prosecute any infringement of the Rockefeller Patent Rights,
      Company may prosecute any infringement of the Rockefeller patent Rights at
      Company’s expense. Company must not settle or compromise any such litigation in
      a manner that imposes any obligations or restrictions on Rockefeller or grants
      any rights to the Rockefeller Patent Rights without Rockefeller’s prior written
      permission. Financial recoveries from any such litigation will be: (a) first,
      applied to reimburse Company for its litigation expenditures; and (b) second,
      as
      to any remainder, retained by Company, but treated as Net Sales for the purpose
      of determining the royalties due to Rockefeller under Section 2.4.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    7.5  Cooperation.
      In any
      litigation under this Article 7, either party, at the request and expense of
      the
      other party, will cooperate to the fullest extent reasonably possible. This
      Section 7.5 will not be construed to require either party to undertake any
      activities, including legal discovery, at the request of any third party, except
      as may be required by lawful process of a court of competent
      jurisdiction.

     

    8.  REPRESENTATIONS;
      DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITIES

     

    8.1  Rockefeller
      and Company each represent that, to the best of their knowledge as of the
      Effective Date, they have the legal right and authority to enter into this
      Agreement and to perform all obligations hereunder. Rockefeller further
      represents that, to the best of the knowledge of the Office of Technology
      Transfer as of the Effective Date, the patent applications listed on Exhibit
      A
      have been assigned to Rockefeller by the inventors named therein and Rockefeller
      owns all right title and interest of such inventors in such patent
      applications.

     

    8.2  THE
      ROCKEFELLER PATENT RIGHTS, ROCKEFELLER TECHNICAL INFORMATION, LICENSED PRODUCTs,
      AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS
      IS” BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ROCKEFELLER MAKES NO
      REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
      TO
      ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MECHANTABILITY, FITNESS
      FOR
      A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE. ROCKEFELLER
      WILL NOT BE LIABLE TO LICENSEE, ITS SUCCESSORS, OR ASSIGNS, OR ANY THIRD PARTY
      WITH RESPECT TO ANY CLAIM: ARISING FROM LICENSEE’S USE OF THE ROCKEFELLER PATENT
      RIGHTS, ROCKEFELLER TECHNICAL INORMATION, LICENSED PRODUCTS OR ANY OTHER
      TECHNOLOGY LICENSED UNDER THIS AGREEMENT; ARISING FROM THE DEVELOPMENT, TESTING,
      MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS; OR FOR LOST PROFITS, BUSINESS
      INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY
      KIND.

     

    9.  INDEMNIFICATION

     

    9.1  Indemnification.
      Company
      will defend, indemnify, and hold harmless Rockefeller, and its trustees,
      officers, faculty, agent, employees, and students (each, an “Indemnified Party”)
      from and against any and all liability, loss, damage, action, claim or expense
      including attorneys’ fees and expenses suffered or incurred by the Indemnified
      Parties (collectively “Liabilities”), arising out of or resulting from (a) the
      development, testing, use, manufacture, promotion, sale or other disposition
      of
      any Rockefeller Patent Rights or Licensed Products by Licensee, sublicensees,
      vendors or third parties; (b) any material breach of this Agreement by Licensee
      or its sublicensees; and (c) the enforcement of this Article 9 by any
      Indemnified Party. Liabilities include, but are not limited to: (x) any product
      liability or other claim of any kind related to use by a third party of a
      Licensed Product that was manufactured, sold or otherwise disposed of by
      Licensee, sublicensees, vendors or third parties; (y) a claim by a third party
      that the Rockefeller Patent Rights or the design, composition, manufacture,
      use,
      sale or other disposition of any Licensed Product infringes or violates any
      patent, copyright, trade secret, trademark or other intellectual property right
      of such third party; and (z) clinical trials or studies conducted by or on
      behalf of Licensee, its sublicensees, assignees or vendors or third parties
      relating to the Rockefeller Patent Rights or the Licensed Products, such as
      claims by or on behalf of a human subject of any such trial or
      study.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    9.2  An
      Indemnified Party entitled to be indemnified pursuant to 9.1 shall promptly
      notify the Company in writing, of any claim or demand with reasonable
      specificity, which the Indemnified Party has determined has given or is
      reasonably likely to give rise to a right of indemnification under this
      Agreement within 45 days of such determination; provided, however, that a
      failure to provide such notice shall not relieve any Indemnifying Party of
      its
      obligations hereunder except to the extent that it has been materially
      prejudiced by such failure. If the Indemnified Party shall notify the
      Indemnifying Party of any claim or demand pursuant to this Section 9.2, and
      if
      such claim or demand relates to a claim or demand asserted by a third party
      against the Indemnified Party that the Company acknowledges is a claim or demand
      for which it must indemnify or hold harmless the Indemnified Party, the Company
      shall have the right to employ counsel of its choice to defend any such claim
      or
      demand asserted against the Indemnified Party provided that the Indemnifying
      Party provides the Indemnified Party with a copy of the claim, answer to the
      claim, periodic updates (including papers filed or served) as requested by
      the
      Indemnified Party an opportunity to review documents to be served and/or to
      be
      filed on behalf of the Indemnified Party with adequate time to allow the
      Indemnified Party sufficient opportunity for review and comment before such
      documents are served and/or filed and the final papers resolving the matter.
      The
      Indemnified Party shall have the right to employ counsel of its choice in the
      defense of any such claim or demand at its own expense. The Company shall notify
      the Indemnified Party in writing, as promptly as possible (but in any case
      ten
      (10) business days before the due date for the answer or response to a claim)
      after the date of the notice of claim given by the Indemnified Party to the
      Company under this Section 9.2, of its election to defend in good faith any
      such
      third party claim or demand. So long as the Company is defending in good faith
      any such claim or demand asserted by a third party against the Indemnified
      Party, the Indemnified Party shall not settle or compromise such claim or demand
      without the Indemnifying Party’s approval. The Indemnified Party shall make
      available to the Company or its agents, at the Company’s cost, all relevant
      records and other material in the Indemnified Party’s possession relating to any
      third party claim or demand.

     

    9.3  Other
      Provisions.
      Company
      will not settle or compromise any claim or action giving rise to Liabilities
      in
      any manner that imposes any restrictions on obligations on Rockefeller or grants
      any rights to the Rockefeller Patent Rights or the Licensed Products without
      Rockefeller’s prior written consent. If Company fails or declines to assume the
      defense of any claim or action within thirty (30) days after notice of the
      claim
      or action and does not notify Rockefeller that it disputes the right to
      indemnification, then Rockefeller may assume the defense of such claim or action
      for the account and at the risk of the Company, and any Liabilities related
      to
      such claim or action will be conclusively deemed a liability of Company. The
      indemnification rights of the Indemnified Parties under this Article 9 are
      in
      addition to all other rights that an Indemnified Party may have at law, in
      equity or otherwise.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    10.  INSURANCE

     

    10.1  Coverages.
      Company
      will procure and maintain insurance policies for the following coverages with
      respect to personal injury, bodily injury and property damage arising out of
      Company’s performance under this Agreement: (a) during the Term, comprehensive
      general liability, including broad form and contractual liability, in a minimum
      amount of $[***] combined single limit per occurrence and in the aggregate;
      and
      (b) prior to the sale of the first Licensed Product, product liability coverage,
      in a minimum amount of $[***] combined single limit per occurrence and in the
      aggregate. The required minimum amounts of insurance do not constitute a
      limitation on Company’s liability or indemnification obligations to Rockefeller
      under this Agreement.

     

    10.2  Other
      Requirements.
      The
      policies of insurance required by Section 10.1 will be issued by an insurance
      carrier with an A.M. Best rating of “A” or better and will name Rockefeller as
      an additional insured with respect to Company’s performance under this
      Agreement. Company will provide Rockefeller with insurance certificates
      evidencing the required coverage within thirty (30) days after the commencement
      of each policy period and any renewal periods. Each certificate will provide
      that the insurance carrier will notify Rockefeller in writing at least thirty
      (30) days prior to the cancellation or material change in coverage.

     

    11.  ADDITIONAL
      PROVISIONS

     

    11.1  Independent
      Contractors.
      The
      parties are independent contractors. Nothing contained in this Agreement is
      intended to create an agency, partnership, or joint venture between the parties.
      At no time will either party make commitments or incur any charges or expenses
      for or on behalf of the other party.

     

    11.2  No
      Discrimination.
      Neither
      Rockefeller nor Licensee will discriminate against any employee or applicant
      for
      employment because of race, color, sex, sexual or affectional preference, age,
      religion, national or ethnic origin, handicap or veteran status.

     

    11.3  Compliance
      with Laws.
      Licensee must comply with all prevailing laws, rules and regulations that apply
      to its activities or obligations under this Agreement. For example, Licensee
      will comply with applicable United States export laws and regulations. The
      transfer of certain technical data and commodities may require a license from
      the applicable agency of the United States government and/or written assurances
      by Licensee that Licensee will not export data or commodities to certain foreign
      countries without prior approval of the agency. Rockefeller does not represent
      that no license is required, or that, if required, the license will
      issue.

     

    11.4  Modification,
      Waiver and Remedies.
      This
      Agreement may only be modified by a written amendment that is executed by an
      authorized representative of each party. Any waiver must be express and in
      writing. No waiver by either party of a breach by the other party will
      constitute a waiver of any different or succeeding breach. Unless otherwise
      specified, all remedies are cumulative.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    11.5  Assignment.
      Company
      many not assign this Agreement or any part of it, either directly or by merger
      or operation of law, without the prior written consent of Rockefeller, except
      that Company may assign this Agreement and the rights, obligations and interests
      of Company, in whole, to any of its Affiliates, to any purchase of all of its
      capital stock or assets or to any successor corporation resulting from any
      merger or consolidation of company with or into such corporation; each of which
      will agree in writing to be legally bound this Agreement. Rockefeller will
      not
      unreasonably withhold or delay its consent, provided that: (a) at least thirty
      (30) days before the proposed transaction, Company gives Rockefeller written
      notice and such background information as may be reasonably necessary to enable
      Rockefeller to give an informed consent; (b) the assignee agrees in writing
      to
      be legally bound by this Agreement; and (c) the assignee agrees to deliver
      to
      Rockefeller an updated Progress Report within forty-five (45) days after the
      closing of the proposed transaction. Any permitted assignment will not relieve
      Company of responsibility for performance of any obligation of Company that
      has
      accrued at the time of the assignment. Any prohibited assignment will be null
      and void.

     

    11.6  Notices.
      Any
      notice or other required communication (each, a “Notice”)
      must
      be in writing, addressed to the party’s respective Notice Address listed on the
      signature page, and delivered: (a) personally; (b) by certified mail, postage
      prepaid, return receipt requested; (c) by recognized overnight courier service
      providing evidence of delivery, charges prepaid; or (d) by facsimile. A Notice
      will be deemed received: if delivered personally, on the date of delivery;
      if
      mailed, five (5) days after deposit in the United States mail; if sent via
      courier, one (1) business day after deposit with the courier service; or if
      sent
      via facsimile, upon receipt of confirmation of transmission provided that a
      confirming copy of such Notice is sent by certified mail, postage prepaid,
      return receipt requested or by courier as set forth above.

     

    11.7  Severability
      and Reformation.
      If any
      provision of this Agreement is held to be invalid or unenforceable by a court
      of
      competent jurisdiction, then the remaining provisions of this Agreement will
      remain in full force and effect. Such invalid or unenforceable provision will
      be
      automatically revised to be a valid or enforceable provision that comes as
      close
      as permitted by law to the parties’ original intent.

     

    11.8  Headings
      and Counterparts.
      The
      headings of the articles and sections included in this Agreement are inserted
      for convenience only and are not intended to affect the meaning or
      interpretation of this Agreement. This Agreement may be executed in several
      counterparts, all of which taken together will constitute the same
      instrument.

     

    11.9  Governing
      Law.
      This
      Agreement will be governed in accordance with the law of the State of New York,
      without giving effect to the conflict of law provisions of any
      jurisdiction.

     

    11.10  Dispute
      Resolution.
      If a
      dispute arises between the parties concerning any right or duty under this
      Agreement, then the parties will confer, as soon as practicable, in an attempt
      to resolve the dispute. If the parties are unable to resolve the dispute
      amicably, then the parties will submit to the exclusive jurisdiction of, and
      venue in, the state and Federal courts located in the State of New York with
      respect to all disputes arising under this Agreement.

     

    11.11  Integration.
      This
      Agreement, together with all attached Exhibits contain the entire agreement
      between the parties with respect to the Rockefeller Patent Rights and the
      License and supersede all other oral or written representations, statements,
      or
      agreements with respect to such subject matter, including but not limited to
      any
      term sheet.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Each
      party has caused this Agreement to be executed by its duly authorized
      representative.

     

    
      	
              THE
                ROCKEFELLER UNIVERSITY

            	
              ROSETTA
                GENOMICS

            
	 	 
	 	 
	
              By:
                

            	/s/ John
              Tooze                                  
              	
              By:

            	
              /s/
                Amir
                Avniel               
                

            
	
              Name:
                

            	John Tooze	
              Name:

            	
              Amir
                Avniel

            
	
              Title:
                

            	Vice President	
              Title:

            	
              President
                and COO

            
	
            	
              Scientific
                and Facility Operations

            	 	
              Rosetta
                Genomics, LTD.

            

    

     

    
 

    
      	
              Address:

            	
              Address:

            
	 	 
	
              The
                Rockefeller University

            	
              Rosetta
                Genomics Inc.

            
	
              Office
                of Technology Transfer

            	
              675
                US Highway One

            
	
              1230
                York Avenue, Box 81

            	
              Suite
                B119

            
	
              New
                York, NY 10021

            	
              North
                Brunswick, NJ 08902

            
	 	 
	
              Required
                copy to:

            	 
	 	 
	
              The
                Rockefeller University

            	
              Mintz
                Levin Cohn Ferris

            
	
              Office
                of General Counsel

            	
              Glovsky
                and Popeo, PC

            
	
              1230
                York Avenue, Box 81

            	
              One
                Financial Center

            
	
              New
                York, NY 10021

            	
              Boston,
                MA 02111

            
	 	
              Attn:
                Jeffrey Wiesen

            

    

     

    
 

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    Rockefeller
      Patent Rights and Sequences Represented

     

    

      
        	 	 	 	 	 	 	 	 	 
	s 	
                [***]

              	 	 	 	 	 	 	 
	 	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
              
	 	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

    

     

    

      11
        sequences

    

     

    
      

        
          	 	 	 	 	 	 	 	 	 
	s 	
                  [***]

                	 	 	 	 	 	 	 
	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                
	 	
                   

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

      
 

    

    
      
        
          	 	11
                  [***]
                  sequences	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	 
	 	
                   

                	
                  [***]

                	
                  [***]

                	
                  
                    [***]

                  

                	
                	
                   

                	
                	
                
	 	
                  
                    [***]

                  

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

    

    
      

        
          	 	15
                  [***]
                  sequences	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                	 

        

      

       

    

    
      
        

          
            	 	5
                    [***]
                    sequences	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	s 	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                  	 

          

           

        

      

    

    
      
        
          	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                
	 	
                   

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

      
        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                
                  [***]

                

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

    

    
      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      
        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

      
        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

    

    
      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
            	
               

            

    

     

    

      130
        Sequences

       

    

    
      	s 	
              [***]

            	
               

            	
            	
            	
            	
            	
            	 

       

      
        
          
            	 	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                  

          

        

        
        

      

    

     

    
 

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]